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REVIEW OF THE LITERATURE 
 
 
1. FAMILIAL BREAST AND OVARIAN CANCER 
 
 
1.1 Familial breast cancer 
Hereditary (familial) cancer essentially means an inherited predisposition to cancer and clustering of 
disease within families is typical of such a dominantly inherited trait. The observation that breast cancer 
runs in families was already documented in the 18th century 1. The highest risks of breast cancer are 
observed among first degree relatives of breast cancer patients 2. Risk becomes higher when the age at 
diagnosis of the proband declines and when bilateral disease is involved 3. The presence of male breast 
cancer is also considered as evidence of familial breast cancer 4. This disease is not completely 
penetrant among susceptible persons; expression depends on gender, age and nongenetic risk factors. 
Overall, 4-10% of the patients with breast cancer show features of the hereditary breast cancer 
syndrome 5-7. In Finland, there are over 3000 new cases of breast cancer diagnosed annually (during the 
years 1990-1997). Given 4-10% frequency of susceptibility allele, up to 300 cases a year may be 
explained by mutations in susceptibility genes (1). 
 
 
1.1.1 Genes that predispose to breast cancer 
Several studies have been carried out to identify breast cancer predisposing genes. Based on a 
segregation analysis in a large sample of families, Newman and colleagues concluded that disease 
clustering was due to an autosomal dominant allele. The highly penetrant susceptibility allele was 
estimated to be rare in the general population (frequency 0.0033) 7. The cumulative lifetime risk of 
breast cancer for gene carriers is predicted to be high (82-92%) while for noncarriers risk is 8-10% 7, 8. 
The major loci for breast cancer predisposition are BRCA1 (p. 10) and BRCA2 (p. 14) while other loci 
contribute to a lesser extent (Table 1) (2). Studies to identify deleted genomic regions in tumor tissue 
have been important in identifying breast cancer predisposing genes. According to the two-hit model of 
cancer development, hereditary cancers arise as a result of a germline mutation in a recessive tumor 
suppressor gene. Mutation is followed by the somatic deletion of the wildtype allele 9.  
 
High frequency of LOH at the tumor suppressor gene TP53 region (17p13.1) has been identified in 
breast cancer samples 10. The gene product of the TP53 gene, the p53 protein, prevents the cell from 
completing the cell cycle if DNA is not properly replicated. The p53 protein also triggers programmed 
cell death (apoptosis) if the damage to the cell is too great to be repaired. The overexpression of p53 in 
primary invasive human breast cancers is caused by a mutation in the TP53 gene in a region that is 
highly conserved 11. However, germline mutations in TP53 account for only a small portion of familial 
breast cancer. The TP53-associated familial breast cancer is typically one feature of the Li-Fraumeni 
syndrome 12, 13.  
 
The PTEN (a.k.a. MMAC1) locus mutated in Cowden syndrome displays frequent LOH in breast 
carcinomas and increased risk of breast cancer is one feature of this syndrome 14. Somatic mutations are 
detected in both breast cancer cell lines and primary cancers. Germline mutations have not been 
identified in breast cancer patients 15 or in members of families with multiple breast cancer patients 16. 
Moreover, linkage studies suggest that PTEN involvement in familial breast cancer is minor 17.  
  9
 
Breast cancer is also a feature of ataxia-telangiectasia, a recessive degenerative disease of childhood. 
The ATM (ataxia-telangiectasia mutated) protein is involved in detecting DNA damage and interrupting 
the cell cycle when damage is found. The ATM gene mutations are associated with increased risk of 
breast cancer 18 but these mutations do not contribute to a large extent to familial breast cancer 19-21.  
 
The tumor susceptibility gene 101 (TSG101) involvement in human breast cancer has been implicated 
based on a high frequency of somatic mutations in primary breast carcinomas 22. However, germline 
mutations have not been detected in this gene in breast cancer patients 23. In addition, the Harvey rat 
sarcoma viral oncogene homolog (HRAS) locus has been implicated in breast cancer. Certain rare 
alleles at the HRAS locus may be associated with susceptibility to breast cancer but clear involvement 
has not been established 24. Along with TSG101 and HRAS, genes on 11q and/or 22q may be involved 
in breast cancer tumorigenesis. The observed number of breast cancer cases is significantly higher than 
expected among the carriers of the constitutional reciprocal translocation t(11; 22)(q23; q11) which is 
the most frequent translocation observed in man 25. 
 
 
Table 1 Genes predisposing to breast cancer 
 
Gene Location OMIM title (2) OMIM entry (2)
BRCA1 17q21 BREAST CANCER, TYPE 1 113705 
BRCA2 13q12 BREAST CANCER 2, EARLY-ONSET 600185 
TP53 17p13 TUMOR PROTEIN p53 191170 
ATM 11q22 ATAXIA-TELANGIECTASIA 208900 
PTEN  
MMAC1 
10q22 PHOSPHATASE AND TENSIN HOMOLOG 
MUTATED IN MULTIPLE ADVANCED CANCERS 1 
601728 
 
 
1.2 Familial ovarian cancer 
A certain number of ovarian cancer cases are familial. Approximately 10% of epithelial ovarian 
carcinoma cases are associated with inheritance of an autosomal dominant genetic trait 26. Like breast 
cancer, ovarian cancer shows an earlier age of onset in hereditary settings 27. Familial ovarian cancer is 
often observed in families with breast cancer, but also without any associated cancers as site-specific 
ovarian cancer 28. Ovarian cancer is also a feature of the hereditary nonpolyposis colorectal cancer 
(HNPCC) syndrome 29, 30. 
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Table 2 Genes predisposing to ovarian cancer  
 
Gene Location OMIM title (2) OMIM entry(2) 
BRCA1 17q21 BREAST CANCER, TYPE 1 113705 
BRCA2 13q12. BREAST CANCER 2, EARLY ONSET 600185 
MSH2 2p22-21 COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 1 120435 
MLH1 3p21 COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 2 120436 
 
 
1.2.1 Genes that predispose to ovarian cancer  
Ovarian cancer is a heterogeneous disease with environmental factors contributing to incidence. The 
gene frequency for the ovarian cancer predisposing gene in the general population is estimated to be 
0.0028 and penetrance 50% by 70 years 31. Presently, a few such predisposing genes are known. The 
hereditary breast and ovarian cancer syndrome is linked to the BRCA1 (p. 10) locus and to a lesser 
extent, to the BRCA2 (p. 14). locus The subtype of HNPCC syndrome with increased risk of ovarian 
cancer is due to mutations in two genes, MSH2 or MLH1. These genes encode proteins involved in 
DNA mismatch repair 30. However, a recent population-based study indicates that germline mutations 
in these four loci contribute to only a minority of cases of early-onset epithelial ovarian cancer 32. Thus, 
the major ovarian cancer locus, if existing, has yet to be found. 
 
 
 
2. THE BREAST CANCER SUSCEPTIBILITY GENE 1 (BRCA1) 
 
 
2.1 The BRCA1 gene is large with two distinct promoters 
The BRCA1 gene is located at 17q21 33. In 1994, a strong candidate for the BRCA1 gene was identified 
34 and predisposing mutations were detected in several breast cancer and ovarian cancer kindreds 35. 
The 24 exons of the BRCA1 span an 81-kb region with an unusually high density of Alu repetitive DNA 
(41.5%) 36. BRCA1 has two promoters generating two distinct transcripts: alpha and beta 37. Neither of 
the promoters contains a TATA box 37. Instead, a 36 bp positive regulatory region mediates the 
promoter activity 38. Both promoters also contain several transcription factor-binding sites at their 5' 
flanking regions 37. The promoter alpha is shared with the adjacent gene (called NBR2) and is bi-
directional. The two transcripts differ having either copy of the duplicated exon 1: exon 1A is first exon 
for transcript alpha and exon 1B for transcript beta. Expression of both transcripts is detected in normal 
and cancer cell lines and in primary breast and ovary tumor tissues. The BRCA1a transcript is the form 
expressed in the mammary gland and the BRCA1b transcript in the placenta 37. 
 
 
2.2 The BRCA1 protein is nuclear and has several functional domains 
The BRCA1 gene product is a nuclear phosphoprotein of 1863 amino acids 34 (Figure 1). This 220-kD 
protein is localized in the endoplasmic reticulum-Golgi complex and in tubes invaginating the nucleus 
39. During mitosis, it localizes with the centrosome 40. The BRCA1 protein has two nuclear localization 
signals (NLS) in exon 11, of which only one (NLS1) is required for proper nuclear localization 41. The 
RING-finger domain 34 situated at the amino-terminal portion of the protein is a member of the 
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extensive family of zinc-binding proteins implicated in cell growth, differentiation and development 42. 
The C-terminal region of the BRCA1 contains a protein-binding site denoted as the BRCT module. The 
BRCT is a globular domain found in proteins involved in repair and cell cycle control 43.  
 
 
 
Figure 1 A schematic illustration of the BRCA1 protein. The corresponding exons are shown above the 
figure. Functional domains and proteins that bind to these domains are shown below the figure. AA = 
amino acid  
 
 
The wildtype BRCA1 protein inhibits the growth of breast and ovarian cancer cell lines 44 and binds to 
a wide array of cellular proteins (Figure 1). The BRCT module and the RING-finger domain of the 
BRCA1 protein mediate most interactions with other cellular proteins. These interacting proteins 
include the DNA repair protein Rad51 45 and the tumor suppressor protein p53 46. The BRCA1 protein 
is also assumed to be involved in transcription, because it binds the RNA polymerase II holoenzyme 47. 
The BRCA1-associated RING domain protein, BARD1 48, is thought to be a critical factor in BRCA1-
mediated tumor suppression 49. Moreover, BRCA1 binds BRCA2 (p. 14) 50 and the BAP1-proteins. 
The BAP1 protein enhances BRCA1-mediated inhibition of breast cancer cell growth 51. The BRCA1 
protein eventually induces the expression of the cyclin-dependent kinase inhibitor p21 Waf1/CiP1 which 
leads to cell cycle arrest 52. The second target gene is the DNA-damage responsive gene GADD45 
(Growth Arrest- and DNA Damage-inducible) 53. Induction of the GADD45 by the BRCA1 protein 
then triggers apoptosis 54.  
 
In breast and ovarian cancer cell lines and in breast cancer biopsies BRCA1 is localized mainly in the 
cytoplasm 34, 55, 56. Location of the naturally occurring 110-kD splice variant BRCA1-delta11b 
(missing NLS1) is also cytoplasmic 41, 57. The dislocation of the BRCA1 protein in breast cancer cells 
may be due to a defect in the NLS mediated pathway of nuclear import 58. 
 
 
 
 
 
EXON
AA
1-10 11 12-24
RING-finger domain BRCT domainNuclear Localization Signals
1 1863
RAD51
p53
RNA polymerase II BARD1
BRCA2
BAP1
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2.3 BRCA1 expression 
The greatest levels of BRCA1 expression are observed during DNA synthesis and mitosis 34, 59. A high 
level of expression is also detected in meiotic germ cells, while premeiotic germ cells express little or 
no BRCA1 mRNA 60. In the mammary gland, the expression is induced during puberty, pregnancy and 
following treatment with 17 beta-estradiol and progesterone 61. BRCA1 expression is initially 
upregulated followed by a reduction below basal levels in response to treatment with DNA damaging 
agents. This reduction of BRCA1 expression is dependent on the presence of wildtype p53 62. 
 
In cancer cell lines, the amount of the BRCA1 mRNA is relatively low 63. Expression is reduced or 
undetectable in breast carcinomas 64, 65 and the mRNA level is markedly decreased during the 
transition from carcinoma in situ to invasive cancer  66. The steady state level of the BRCA1 mRNA is 
elevated by estrogen and blocked by antiestrogens 67 in breast cancer cell lines. This effect is mediated 
through the estrogen receptor 68.  
 
 
2.4 Pathological variants of the BRCA1 gene  
 
2.4.1 There is a wide spectrum of BRCA1 germline mutations  
Somatic mutations involving the BRCA1 gene have been detected in primary breast and ovarian tumor 
samples at a low frequency 69. Contrary to somatic mutations, there are multiple disease-causing 
mutations in the germline. The number of distinct mutations exceeds 900. Some 400 of these are found 
recurrently. All mutation types are present, but the majority of mutations are nucleotide substitutions 
followed by small deletions (3,4). Large germline deletions, which appear to result from homologous 
recombination between closely related Alu repeats 70-72, have also been detected. Carriers homozygous 
for BRCA1 mutations have yet to be found, suggesting that homozygosity is lethal in humans. 
Segregation of two different frameshift mutations in a single family has been detected; however, no 
individual carried both mutations 73. 
 
 
2.4.2 Germline mutations are found at high frequency in families with multiple affected members  
Estimates obtained from population-based studies suggest that the frequency of the mutated allele in the 
general population is low (0. 0006) 74. The proportion of breast cancer cases diagnosed in the general 
population below the age of 40 due to BRCA1 mutation is approximately 5%. The corresponding 
estimate for ovarian cancer cases is 5.7% 74. Of families with multiple breast cancer cases, 45-52% are 
thought to be BRCA1-associated 75-77. Of the families featuring the hereditary breast and ovarian cancer 
syndrome, BRCA1 is estimated to explain up to 76-90 % of families 75, 77, 78. In certain ethnic groups 
mutations appear with a higher frequency, for instance, the 185delAG mutation is present at 1% 
frequency among Ashkenazim 79. 
 
 
2.4.3 BRCA1 germline mutations predispose to several cancer types  
Obtained estimates of the cumulative risk of breast cancer (54% by 60 years) and ovarian cancer (30% 
by age 70) are derived from families showing genetic linkage to BRCA1 80. The risk of ovarian cancer 
is presumed to differ with specific cancer-disposing mutation. A significant correlation is observed 
between the location of the mutation and the ratio of breast to ovarian cancer incidence within the 
family. Mutations in the 3-prime third of the gene are associated with a lower proportion of ovarian 
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cancer 81, 82. There is also experimental evidence for the relative susceptibility to ovarian versus breast 
cancer. Ovarian cancer cell growth is not affected by BRCA1 mutations in the 5-prime portion of the 
gene but is inhibited by 3-prime BRCA1 mutations 83. BRCA1 mutation also predisposes carriers to 
prostate and colon cancer and the cumulative risks by 70 years are 8% and 6%, respectively 84. It has 
been noted that the age at breast cancer diagnosis is earlier among those mutation carriers who carry 
very long trinucleotide (GAG) repeats in the androgen receptor gene. This suggests that pathways 
involving androgen signaling may affect the risk of BRCA1-associated breast cancer 85. The variable 
penetrance of BRCA1 suggests that several genetic and nongenetic factors play a role in tumorigenesis.  
In addition, the HRAS gene minisatellite polymorphism has been proposed as one possible genetic 
modifier of penetrance. The risk of ovarian cancer is 2.11 times greater for those BRCA1 mutation 
carriers harboring one or two rare HRAS alleles compared to carriers with only common alleles. 
Susceptibility to breast cancer does not appear to be affected by the presence of rare HRAS alleles 86. 
 
 
2.4.4 The survival of mutation carriers does not seem to differ from sporadic cases 
Most studies have not found a significant difference in the survival of breast cancer patients with 
BRCA1 mutations when compared to controls 87, 88 but also conflicting reports have been published 89, 
90. Results are presumed to be conflicting at least in part because of methodological problems. Rubin 
and coworkers suggested a favorable clinical course in primary epithelial ovarian cancer patients with 
BRCA1 mutation when compared to sporadic ovarian cancers 91. However, other authors have found 
contradicting results suggesting that survival in familial ovarian cancer cases is worse than in sporadic 
cases, whether or not a BRCA1 mutation is present 92. Johannsson and colleagues have suggested no 
difference in the survival of ovarian cancer patients with BRCA1 mutations when compared to controls 
87. 
 
 
2.4.5 Somatic deletions encompassing the BRCA1 locus are frequent in breast cancer tissue 
Loss of heterozygosity on chromosome 17 is common genetic alteration in breast cancer tumors 93 and 
LOH is frequently observed at the BRCA1 region 94. In both tumors from families linked to the BRCA1 
gene 95 and individuals carrying BRCA1 mutations 96, the observed allele loss involves the wildtype 
allele. Genome-wide CGH analysis of breast cancers from BRCA1 mutation carriers shows that losses 
of 5q, 4q, 4p, 2q and 12q being significantly more common than in the control group 97. The loss of the 
whole chromosome 17 is also a relatively frequent event in ovarian tumors. LOH of the BRCA1 gene 
region is observed in 50% of tumors 98. LOH of the BRCA1 region is also detected in endometrial 
cancer 99 and gastric carcinomas 100. The molecular pathogenesis and histological phenotype of tumors 
from BRCA1 mutation carriers differ from mutation-negative cases as well. Breast cancers occurring in 
BRCA1 mutation carriers have higher levels of p53 expression and a higher proliferation rate 101. 
BRCA1 mutation carrier cell line shows aneuploidy, an acquired TP53 mutation with the loss of the 
wildtype allele and an acquired homozygous deletion of the PTEN gene 102. 
 
 
2.5 Murine Brca1 
The mouse homologue of BRCA1 maps to chromosome 11, an area with extensive homology to the 
human chromosome 17 103. Null mice die early in embryonic development.  The mutant embryos are 
poorly developed and show a variety of neuroepithelial defects 104 and reduced cell proliferation 105. 
Heterozygous mice have defective cell cycle control and chromosomes contain multiple functional 
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centrosomes 106. Excision of exon 11 of the Brca1 causes abnormal ductal development and increased 
apoptosis in epithelial cells 106. Disruption of the Brca1 causes genetic instability and triggers further 
alterations, including inactivation of p53 107. After about 1 year of age, heterozygous Brca1 female 
mice show no evidence of cancer 104, 105. 
 
 
 
 
3. THE BREAST CANCER SUSCEPTIBILITY GENE 2 (BRCA2) 
 
 
3.1 The BRCA2 locus is situated at 13q12 
Stratton and coworkers presented strong evidence against linkage to BRCA1 in families with at least 
one case of male breast cancer 108. Strong evidence of linkage to the BRCA2 region was shown in 
families characterized by multiple cases of male breast cancer 109, 110. The BRCA2 gene was localized 
to region 13q12 111. BRCA2 is composed of 27 exons (the first exon is noncoding) distributed over 
roughly 70 Kb of genomic DNA 112. Simple sequence variation is frequent both in the coding and 
noncoding region 113. 
 
 
3.2 The BRCA2 protein has no similarity to other known proteins 
The gene product of the BRCA2 gene is a 3418 amino acid (390-kD) nuclear protein and it bears no 
similarity to other known proteins 112 (Figure 2). The 5-prime portion of the exon 11 contains repeated 
sequences termed BRC motifs that are conserved in mammalian BRCA2 proteins 114. The BRC module 
consists of four 30-residue repeats 115. A sequence in exon 3 shows sequence similarity to the 
activation domain of the JUN proto-oncogene. The activation potential within exon 3 is under negative 
control by two inhibitory regions present immediately on either side of the exon 3 116. The human 
RAD51 binds directly to the BRC repeats 117. Brca2 physically and functionally interacts with p53 118 
and it has been shown to acetylate the histones H3 and H4 when bound to the  P/CAF transcriptional 
co-activator 119. 
 
 
3.2.1 BRCA2 is expressed in several tissues 
Expression BRCA2 mRNA is observed in several tissues: breast epithelium, thymus, testis, placenta, 
lung, ovary and spleen 112, 120. Expression is initiated before DNA synthesis 121 and it is associated 
with proliferation both in normal 122 and tumor-derived breast epithelial cells 123. The steady state 
levels of BRCA1 and BRCA2 mRNAs are coordinately elevated by estrogen but not progesterone and 
blocked by antiestrogens 67. BRCA2 mRNA undergoes differential splicing giving rise to a variant 
protein BRCA2a. Both BRCA2 and BRCA2a are present at high levels in thymus and testis but 
moderate levels in the mammary gland and prostate suggesting that they have a role in the development 
and differentiation of these tissues 124. 
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Figure 2 Schematic representation of the BRCA2 protein. The functional domain, the BRC module and 
proteins binding to the module are presented below the figure. The corresponding exons are presented 
above the figure.AA=amino acid 
 
 
3.3 Pathological variants of the BRCA2 gene 
 
3.3.1 The germline mutation spectrum of BRCA2 resembles that of BRCA1 
Wooster and colleagues reported first mutations in the BRCA2 gene 120 followed by several other 
research groups 125, 126. Somatic mutations in the BRCA2 gene are rare 127-129. On the contrary, the 
number of germline mutations is high. There are over 900 mutations, of which 620 have been found 
only once. The mutation spectrum closely resembles that of BRCA1 (3,4). However, large deletions are 
more rare in the BRCA2 gene than in BRCA1, with only one case reported so far 130. No homozygotes 
for BRCA2 mutations have been observed, although certain mutations have an exceptionally high 
carrier frequency 131.  
 
 
3.3.2 BRCA2 is associated with fewer breast cancer cases than BRCA1 
In families with multiple breast cancer cases, the disease is estimated to be due to mutations in the 
BRCA2 gene in 32% of families 77. Mutations in the BRCA2 gene account for 4% of male breast cancer 
cases without family history 132 and for 14% of cases with family history 125.  Population-based 
estimates predict that of early-onset breast cancer cases 3.4% carry BRCA2 mutations 133. As in 
BRCA1, certain mutations are enriched: the 999delTCAAA mutation frequency is 0.6 % in the 
Icelandic population 131, 10.4% in female and 38% in male breast cancer cases 134. Overall, BRCA2 is 
associated with fewer breast cancer cases than BRCA1 135. Recently, it was proposed that common 
variants might confer an increased risk of breast cancer also. The HH homozygotes for the 
polymorphism N372H (exon 10) have a 1.31-fold greater breast cancer risk than the NN homozygotes. 
Moreover, the HH variant appears to affect fetal survival in a sex-dependent manner 136. 
3.3.3 BRCA2 mutations predispose to cancers in several organs 
The estimated cumulative risk of breast cancer in families showing genetic linkage to BRCA2 is 80% in 
females and 6% in males by the age of 70. These risks are similar to the ones estimated for BRCA1 
mutation carriers. However, there is some evidence of a lower risk of breast cancer in BRCA2 carriers 
under 50 years of age 77, 137. A significant excess of ovarian cancer is observed in gene carriers and the 
BRC moduleAA  1
3418
2-10EXON 11 12-27
RAD51
p53
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ovarian cancer risk is 27% by the age of 70 77. Variation in phenotypic risk has been observed in 
mutation carriers. Truncating mutations in carriers with the highest risk of ovarian cancer relative to 
breast cancer are clustered in a region of approximately 3.3 Kb in exon 11 138. Laryngeal, prostate and 
pancreatic cancers are also frequent in individuals carrying BRCA2 mutations 134, 139, 140. Several 
studies have shown that despite their younger age at presentation, breast cancer patients harboring 
BRCA2 mutations have a similar prognosis when compared with sporadic breast cancer patients 88, 141, 
142. 
 
 
3.3.4 Loss of heterozygosity involving the BRCA2 region is seen in various tumor types  
In breast carcinomas, LOH involving the BRCA2 region is found in 51% of studied samples 94. In 
tumors from families showing genetic linkage to BRCA2, LOH at the BRCA2 region is seen frequently. 
In most of the cases, there is a confirmed loss of the wildtype allele 143. In BRCA2 mutation carriers, 
LOH at the BRCA2 region is observed in tumors of the prostate, ovary, cervix, colon, male breast, and 
ureter. In addition, breast tumors from female carriers demonstrate loss of the wildtype chromosome 
144. A CGH-based analysis revealed that tumors from BRCA2 mutation carriers exhibited a significantly 
higher number of chromosomal aberrations than sporadic tumors. The most common genetic changes 
were gains of 8q, 20q and 17q and losses of 13q and 6q 145. The histology of BRCA2 mutation-positive 
cases differs from sporadic cases and from BRCA1 mutation-positive ones. The findings suggest that 
breast cancers in these three groups have a different natural history 146.  
 
 
3.4 Murine Brca2 
The mouse Brca2 maps to the distal end of chromosome 5 and it is expressed in thymus, testis and 
ovary 147. In mammary epithelial cells Brca2 expression is induced during puberty, pregnancy and in 
response to glucocorticoids. Both the Brca1 and Brca2 genes are highly expressed in rapidly 
proliferating cells, with the expression peaking before DNA replication begins 148. Cells that harbor 
truncated Brca2 spontaneously incur chromosomal rearrangements and DNA breaks during division 
149. These cells also exhibit hypersensitivity to DNA damage 150. The majority of homozygous mutant 
mice die prenatally or perinatally. The mutants that survive to adulthood die with thymic lymphomas 
between 12 and 14 weeks of age. Heterozygote mice are free of tumors 151. 
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4. THE FINNISH POPULATION HAS A UNIQUE HISTORY AND GENE POOL 
 
Finns are described as outliers among European populations with the gene pool showing a unique 
pattern. The genetic isolation of Finland is due to both geographical and linguistic reasons. The Finnish 
language is a member of the Finno-Ugric language family 152. Genetically Finns are close to Indo-
European speakers with an estimated 90% of genes being European, assumed to be the outcome of long 
close contact with Germanic populations 153. 
 
Analysis based on mitochondrial mutations suggests that the founding population went through a 
bottleneck approximately 4000 years ago, presumably when populations using agriculture and animal 
husbandry arrived in Finland 154. There is not a full agreement between historical data and genetic data 
on the origin of Finns. The single origin model proposes a single route of immigration over the Gulf of 
Finland 155, 156. A dual-origins model based on HLA genes 157 and Y chromosome markers 158 
proposes that two different groups settled in Finland: one from the east and the other from the south via 
the Gulf of Finland 159. However, both models agree that the population has remained an isolate and 
that the population expansion started 2000-2500 years ago in southern and western parts of the country. 
The number of founders was small and this group founded the population known today as Finns (5.2 
million). The northern and eastern parts of the country were settled mainly after the 16th century. This 
expansion was characterized by sub-isolates with a relatively small number of individuals. Genetic drift 
worked in these sub-isolates modifying the gene pool resulting in enrichment of mainly recessive 
diseases denoted as The Finnish Disease Heritage. Originally, the concept consisted of some 10 
diseases 160 . Subsequently it was widened to comprise some 30 diseases 156. The geographical 
distributions of rare alleles show a distinct pattern according to time the of origin 160. 
 
Recently expanded populations such as Finns are suitable to map single disease genes affected by 
recent mutations. This characteristic has been utilized in several linkage disequilibrium studies. A 
simplified population genetics model was introduced by Hästbacka and co-workers 161 and since, 
several genes have been localized 156. In complex diseases, the localization of disease genes has been 
aided by using families either from only the late settlement areas or from a sub-isolate 162. 
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5. METHODS  
 
 
5.1 Methods for gene localization 
Gene localization is the first step in positional cloning. Genetic linkage analysis is the major technique 
for the initial localization of genes and several statistical approaches exist. Novel gene localization 
methods are constantly being developed to accompany linkage analysis. 
 
 
5.1.1 Genetic markers and maps 
A genetic linkage map shows the relative locations of specific DNA markers along the chromosome. 
Polymorphic DNA sequence differences between individuals are used as such markers. Restriction 
fragment length polymorphisms were the first markers used in genetic mapping. These are sequence 
variations in DNA at sites that can be cleaved by restriction enzymes 163. The next generation of 
markers was based on short repeated sequences that vary in the number of repeated units. These 
minisatellite markers were detected by electrophoresis 164. Weber and May introduced microsatellites 
in which the repeated sequences are 2-4 bases long. These short tandem repeats are at present the 
standard method for genetic mapping. PCR is performed with a fluorescent primer and products are 
directly analyzed on an automated instrument 165. The latest generation of markers, single nucleotide 
polymorphisms, was recently introduced. Densely spaced biallelic markers are expected to advance 
linkage studies 166. 
 
The human genetic linkage map is constructed by observing how frequently two markers are inherited 
together. Recombination frequency provides an estimate of the distance between two markers. 
Distances between markers are measured in terms of centiMorgans (cM). Distance over which 
probability of recombination is 1% is known as 1 cM. A genetic distance of 1 cM is roughly equal to a 
physical distance of 1 million bp (1 Mb). The probability that a recombination occurs between two loci 
is the recombination fraction, theta. Thus, theta is a measure of genetic distance between two loci. 
Inherited disease is located on the genetic map by following the inheritance of a DNA marker present in 
affected individuals 167. 
 
 
5.1.2 Statistical methods used for gene localization 
Statistical methods applied for linkage analysis are often divided into parametric and nonparametric 
methods. The parametric methods involve testing whether the inheritance pattern fits a specific model 
for a trait-causing gene. Parametric methods require the inheritance model to be defined and are 
sensitive to misspecification of the model 168, 169. Nonparametric methods do not require the 
inheritance model to be known. In addition, nonparametric methods allow analysis in less optimal 
situations 170. Before actual genotyping is performed, the power to detect linkage in a given set of 
families can be estimated by simulation 171. In addition to genetic linkage, one can study allelic 
association.  
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5.1.2.1 The LOD-score method is the standard parametric method of linkage analysis 
The LOD score method is the standard parametric method when analyzing human pedigrees. The LOD 
scores are obtained by calculating the overall likelihood of the data under two alternative assumptions: 
that the two loci are linked with the given recombination fraction value (theta) and that they are 
unlinked. Likelihood is similar to probability and it is dependent on the distance between the two loci. 
The ratio of those two likelihoods is called a likelihood ratio and it indicates the odds for or against 
linkage. The logarithm to the base 10 of this ratio is the LOD score. This procedure is repeated for a 
selection of theta values. The theta value that gives the highest LOD score represents the best estimate 
of the distance between the two loci. The power to detect linkage depends on the number of informative 
meioses, almost regardless of family structure. An LOD score of three or over is considered as 
conclusive 172. 
 
If linkage cannot be established based on the given set of pedigrees, it is studied whether a subset of the 
pedigrees shows collectively evidence of linkage. One can explicitly allow genetic heterogeneity by 
inclusion of an admixture parameter (alpha) specifying the proportion of linked families. The LOD 
score can be constructed under heterogeneity depending on both alpha and theta. Maximizing the LOD 
score provides estimates of both alpha and theta 173. The probability of obtaining false evidence of 
linkage depends on several parameters. Such parameters are the correctness of the marker allele 
frequencies, pedigree structure, number of the families in the sample and the threshold of accepting 
linkage. These effects are most pronounced in small pedigrees when essential individuals are 
unavailable for typing. Difficulties in linkage analysis include incomplete information (unfavorable 
structure of the pedigrees and uninformativeness of the genetic markers) as well as incomplete 
penetrance of the susceptibility gene and presence of sporadic cases in the families 170. 
 
Multipoint linkage is used for more precise gene localization by typing a series of markers. Multipoint 
offers added power, especially with loci with poor information content or with small samples. LOD 
scores are computed for different locations and results are presented in the form of a graph. The LOD 
score is plotted against the position along the chromosome. The evidence in favor of particular location 
is expressed in terms of “relative odds” of a particular order. When odds of 1000:1 or greater are 
obtained, it is conventionally regarded as conclusive 167. Multipoint includes some computational 
difficulties when the number of loci increases. In addition to localization, multipoint linkage is used for 
constructing maps of genetic markers by marker typings on large reference families 174. 
 
 
5.1.2.2 Nonparametric methods of linkage analysis  
Nonparametric methods test whether the inheritance pattern deviates from expectation under 
independent assortment. These methods do not depend on a model but on counting marker alleles or 
haplotypes between affected relatives. Linkage is measured by allele sharing. Typically affected 
individuals are sibling pairs but analyses can be extended to other types of relative pairs 175. The APM 
(Affected Pedigree Member) approach enables the use of pedigrees with more than two affected 
individuals 176. 
 
 
5.1.2.3 Allelic association 
Allele-sharing methods involve direct testing of candidates by looking for associations between 
particular alleles and disease by comparing allele frequencies in affected individuals and matched 
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controls. The choice of appropriate control group is essential. The observed high-risk allele does not 
need to be the disease causing allele itself. A more likely explanation for association is linkage 
disequilibrium (LD). LD occurs when a particular marker allele lies so close to the disease 
susceptibility allele that these alleles co-segregate over many generations. The same allele will be 
detected in affected individuals in multiple apparently unrelated families 177. Linkage disequilibrium 
can arise in a number of different ways. The most common situations are after recent admixture of two 
previously isolated populations 178 or, when a large population has expanded rapidly from a relatively 
small founder population 161. When population association has been established, analysis may be 
extended to families. The most widely used test, TDT (transmission disequilibrium test) evaluates the 
transmission of associated marker allele from a heterozygous parent to the affected offspring 179.  
 
 
5.1.3 Novel methods for gene localization 
Novel methods test either the differences in genomic DNA or variations in gene expression. 
Comparative genomic hybridization produces a map of DNA sequence copy number as a function of 
chromosomal location throughout the entire genome. Regions of gains or losses of DNA sequences are 
seen as changes in the ratio of the intensities of the used fluorochromes along the target chromosome 
180. Genome-scale LOH analysis is labor-intensive. Contrary to LOH,  CGH allows the identification of 
chromosomal imbalances in a comprehensive manner, providing genome-scale information in a single 
experiment. With CGH, it is possible to identify recurrent chromosomal gains and losses as starting 
points for the characterization and isolation of pathogenetically relevant cancer genes. The power of 
CGH in identifying putative tumor suppressor loci has been demonstrated in Peutz-Jeghers syndrome 
where CGH in hamartomas pinpointed a recurrently deleted region. Subsequent targeted linkage 
analysis revealed a high-penetrance locus in 19p13.3 181. This novel locus encodes the serine/threonine 
kinase STK11 182. However, DNA gains and losses in tumor cells do not occur entirely at random. 
Models that relate tumor progression to the occurrence of DNA gains and losses have been developed 
to facilitate the distinction of primary events involved in cancer initiation from the numerous events 
that arise during cancer progression 183. 
 
 
The multiple genetic alterations in cancer result in complex changes in the expression of many genes. 
Analysis of gene expression profiles of tumors using a DNA microarray enables the identification of 
up-regulated or down-regulated genes. The modification cellular phenotype by successive genetic 
alterations and the examination the resulting expression profiles may facilitate the identification of 
tumor suppressor genes 184. The application of the DNA microarray technology may also facilitate gene 
identification when mutations result in changes in the mRNA level of the disease gene 185. 
 
 
5.2 Methods for mutation detection  
Changes in the genome of an individual can lead to a disease phenotype. Such changes can occur in a 
number of different ways, such as deletion, insertion, fusion, point mutation, or amplification of 
unstable sequences. Changes in DNA structure may occur both in germ cells and somatically. 
Methodologies used in screening for mutations differ in sensitivity and thus biases the types of 
mutations found. No currently available single technique can guarantee the identification of all types of 
mutations 186. In addition, mutations of uncertain clinical significance may be identified. The clinical 
significance of a mutation can be determined by studying whether the mutation segregates with the 
  21
disease in a given family and whether the allele has a higher frequency in patients than in the general 
population. Ultimately the significance of the mutation can be revealed by direct protein function assays 
187. 
 
 
5.2.1 Screening methods for finding unknown mutations 
The PCR method is often used for generation of the DNA fragments or is in itself used as part of the 
detection method. One set of methods relies on differences in electrophoretic mobilities between 
wildtype and mutant nucleic acids. The second group of methods is based on the cleavage of 
mismatches in heteroduplexes. The third group uses mismatch-binding proteins in heteroduplexes. 
Direct sequencing is considered as the gold standard method of mutation detection 188. The dideoxy 
(Sanger) method for sequencing is the most widely used variant 189. 
 
SSCP (single strand conformation polymorphism) is based on the electrophoretic mobility of single-
stranded nucleic acids. Mobility depends not only on size but also on sequence and most single base 
changes can be detected as mobility shifts 190. Using different conditions sensitivity can be increased 
191. In DGGE (denaturing gradient gel electrophoresis), dsDNA is electrophoresed through a gradient 
of increasingly denaturing conditions. Sequence differences result as differences in partial melting 
behavior of the DNA fragments 192. In heteroduplex analysis (HA), the heteroduplex molecules that 
form between a mutant and a wildtype DNA strand are distinguished from homoduplex molecules upon 
gel electrophoresis 193. Modifications and enhancements of the HA method have been developed that 
increase the sensitivity of detection of single-base pair alterations 194. Chemical or enzymatic cleavage 
of mismatch is based on the formation of heteroduplexes between wildtype and mutant sequences in the 
sample. Strands are cleaved at the site of mismatch chemically 195 or enzymatically 196. The protein 
truncation test (PTT) involves in vitro-coupled transcription and translation of PCR products, resolved 
by SDS-PAGE analysis. The size of the translation product pinpoints the position of the stop codon in 
the corresponding PCR product fragment. It should be noted that mutations located very close to the 
primer binding sites may escape detection. Designing overlapping sets of primers can alleviate this 
problem 197. Mutations involving large genomic rearrangements can be detected by Southern blotting 
198. 
 
 
5.2.2 Diagnostic methods for finding known mutations 
The simplest ways to screen for known mutations is to use naturally occurring restriction enzyme 
cleavage sites 163. Artificial restriction sites may be introduced using mismatched primers 199. The 
allele-specific amplification (ASA) method relies on two parallel reactions where only one allele of 
either mutant or wildtype is amplified, and several variants of this technique are available 188. In allele-
specific oligonucleotide (ASO) hybridization one uses probes which can detect single base substitutions 
in PCR-amplified DNA. An allele-specific oligonucleotide will only anneal to sequences that match it 
perfectly, a single mismatch being sufficient to prevent hybridization under appropriate conditions 200. 
Oligonucleotide-ligation assay (OLA) is based on the covalent attachment of labeled reporter 
oligonucleotide to an immobilized target oligonucleotide. The sample DNA serves as the template. In 
the case of a mismatch no ligation will occur. The assay products are resolved electrophoretically from 
one another and from unligated probes under denaturing conditions 201. Minisequencing has several 
variants, which are all based on the extension of the 3’ end of the primer by a single, complementary 
nucleotide 202, 203. 
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AIMS OF THE PRESENT STUDY  
 
 
1.  To determine the prevalence and spectrum of the BRCA1 and BRCA2 mutations in Finnish 
 breast and ovarian cancer families (studies I and II). 
 
 
2.  To further characterize the most common BRCA2 mutation in Finland, 999delTCAAA, using 
 genealogical records and haplotype data (study IV, unpublished). 
 
 
3.  To find evidence of a third breast cancer-predisposing gene in Finnish breast cancer families 
 (study III). 
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MATERIAL AND METHODS 
 
 
1. ETHICAL IMPLICATIONS 
 
Appropriate permission was obtained from the Ministry of Social Affairs and Health. Written informed 
consent was obtained from all patients and relatives donating blood samples for the genetic analysis. 
The DNA samples were coded and no data from the research work was provided to the patients or 
family members. 
 
 
2. KINDREDS AND TUMOR SAMPLES  
 
2.1 Kindreds included in the BRCA1 and BRCA2 mutation analyses (I,II) 
One hundred patients with a positive family history were included in the study (Table 3). The patients 
were originally selected from the following three cohorts: 
A. Breast cancer patients diagnosed below 40 years of age who were treated at the Department of 
Oncology of the Helsinki University Central Hospital (HUCH) during the years 1985–1993. 
B. Breast cancer patients diagnosed with bilateral breast cancer who were treated at the Department of 
Oncology (HUCH) during the years 1985–1993. 
C. Unselected breast cancer patients who were treated at the Department of Oncology (HUCH) between 
November 10th 1993 and April 30th 1995. 
 
Patients were interviewed for family history of breast cancer and the patients with positive family 
history were included in the study. The genealogy of these patients was confirmed using church-parish 
registries. The diagnoses of the patients and relatives were confirmed using hospital records of the 
HUCH Department of Oncology and the Finnish Cancer Registry. In addition, DNA samples from 93 
unrelated healthy individuals were used as controls. The study population and the control group were of 
Finnish (Caucasian) origin. 
 
Table 3 Breast and ovarian cancer cases in families included in mutation analyses 
 
Number and type of cancer cases in the family Number of families 
Four or more breast cancer cases 23 
Four or more breast cancer  cases and ovarian cancer 14 
Three breast cancers 50 
Three cancers, breast and ovarian 11 
Two cancers, breast and ovarian 2 
Total 100 
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2.2 Kindreds included in the haplotype analysis of the BRCA1 and BRCA2 regions (II) 
Haplotype analysis was carried out in 12 families in which BRCA1 or BRCA2 mutations had not been 
detected. Six of the families had four or more cases of breast cancer and six had four or more cases of 
breast and ovarian cancer. All available individuals were genotyped. 
 
 
2.3 Kindreds included in the haplotype analysis of the 999delTCAAA mutation  
families (IV, unpublished) 
Ten Finnish kindreds carrying the 999delTCAAA mutation ascertained at four research centers were 
included in the study. Two of these families were from the cohort of 100 families described in the 
Material and Methods section 2.1. A total of 54 individuals were genotyped, of these, 28 were 
mutation carriers and 26 noncarriers. Mutation carrier status had been determined in all individuals 
by ASO hybridization. The birthplaces of grandparents to the proband were traced using church 
parish records.  
 
 
2.4 Tumor samples used in the CGH analysis (III) 
A total of 61 tumor specimens from 37 non-BRCA1/BRCA2 breast cancer families were selected for the 
CGH analysis from the Helsinki University Central Hospital (Finland, 24 tumors), Lund University 
Hospital (Sweden, 23 tumors) and The University Hospital of Iceland (14 tumors). All tumors 
originated from families with three or more cases of breast cancer.  
 
 
2.5 Kindreds included in the linkage analysis (III) 
The 77 families for linkage analysis were identified through the Oncology clinics of the Helsinki and 
Tampere University Hospitals, Lund University Hospital in Sweden and the Department of Pathology 
at the University Hospital of Iceland. Twenty-three of these were families included in the CGH analysis 
and from which blood samples from multiple affected were available. Paraffin tissue samples were 
obtained from deceased patients when available. The initial set of families consisted of 57 Finnish 
families and the second set of 12 Icelandic and 8 Swedish families. 
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3.  METHODS 
 
 
3.1 Methods used in the BRCA1 and BRCA2 mutation analyses (I-II)  
All 100 families were analyzed for the coding regions (including splice boundaries) of both the BRCA1 
and BRCA2 genes using the combined HA/SSCP method. Detection of the HA/SSCP bands was 
performed by silverstaining as described in reference Gayther et al 1995 81. The large exons (exon 11 of  
BRCA1, 10 and 11 of BRCA2) were analyzed using PTT. Primer sequences used in these analyses are 
described in reference Friedman et al 1997 132. When aberrant mobility was detected on HA/SSCP or 
PTT gels, the variants were re-amplified from genomic DNA and directly sequenced. ASO 
hybridization was used for analyzing polymorphic status of the changes and for confirming the 
segregation of the putative mutation in other family members. Oligonucleotides used in ASO 
hybridization assays were designed using genomic sequences of the BRCA1 and BRCA2 genes (5). 
Seventy index cases from these families were also sequenced for the entire coding region of the BRCA1 
gene (Myriad Genetics) and three index cases for the BRCA2 gene. The principal laboratory methods 
used are listed in Table 4. 
 
 
Table 4 Laboratory methods used in studies I-IV 
 
Laboratory 
method 
Used in study  Reference 
ASO I,II, IV Saiki et al 1986 200 
PTT I,II Roest et al 1993 197 
HA I,II Nagamine et al 1989 193 
SSCP I,II Orita et al 1989 190 
Sequencing I,II Sanger et al 1977 189 
Genotyping III, IV Smith et al 1995 204  
CGH III Kallioniemi et al 1992 180 
 
 
3.2 Polymorphic markers used for the haplotype analysis of the BRCA1 and BRCA2 regions (II) 
Polymorphic microsatellite repeat markers for the 17q21 region (BRCA1) haplotype analysis were 
D17S1185, D17S855 and D17S579 and markers for the 13q12 region (BRCA2) D13S260, D13S1701 
and D13S267.  
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3.3 Polymorphic markers used for the haplotype analysis of the 999delTCAAA mutation families 
(IV, unpublished) 
Haplotype analysis of the ten families included 24 markers spanning a genomic region of 29 cM 205, 206 
(Figure 3). The map distances for microsatellite markers were obtained from Généthon (6). Haplotypes 
were constructed with Genehunter and manually assuming minimal parsimony.  
 
 
Figure 3 The polymorphic markers studied in the 999delTCAAA families. The region between markers 
D13S 260 and D13S171 harboring the BRCA2 gene is shown in greater detail. * This 1.6cM region is 
shown out of proportion for clarity.  
 
 
3.4 CGH and related data analysis (III) 
CGH was performed essentially as described in reference Kallioniemi et al. 1992 180. To select which 
recurrent events are most likely to be nonrandom (truly related to the cause of tumor development and 
progression), we used a well-established method of Brodeur et al. 1982 207. 
 
 
3.5 Genotyping of the families and related data analysis (III) 
Genotyping was performed using 23 genetic markers from the Genome Database, distances as given by 
Généthon (6,7). The software used in the analysis is listed in Table 5. The population frequency of the 
disease allele was set to 0.0033 8. The autosomal dominant model was used. The age-dependent 
penetrances for mutation carriers and phenocopies are shown in Table 6 76. Females diagnosed with 
breast cancer were coded as affected and females with ovarian cancer as unknown. The statistical 
significance of the peak 2-point LOD score with marker D13S1308 was assessed by simulation, using 
the principles outlined in Ott 1999 208.  
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Table 5 Software used in study III 
 
Software Analysis References 
Pedcheck Genotype data inconsistency 209 
FASTLINK software Model dependent LOD score 210, 211, 212, 213 
HOMOG2 Locus heterogeneity 1 208 
HOMOG3R Locus heterogeneity 2 208 
SIBPAL (S.A.G.E.) Model-independent affected sib-pair analysis (8) 
SIB-PAIR Population-specific allele frequencies 214 
FASTLINK Multipoint linkage analyses 211, 212, 213 
HOMOG Multipoint heterogeneity LOD scores 208 
Genehunter Multipoint linkage analyses 170 
1 BRCA2 and the novel locus 
2 BRCA1 and the novel locus 
 
 
 
 
Table 6 The age-adjusted penetrances for mutation carriers and the phenocopy rates used in the 
linkage analysis. 
 
 < 30 y. 30-39 y. 40-49 y. 50-59 y. 60-69 y. 70-79 y. > 80 y. 
Penetrance 0.00167 0.01276 0.02305 0.01711 0.0126 0.00908 0.00654 
Phenocopy 
Rate 
0.00002 0.00026 0.00112 0.00137 0.00226 0.00218 0.00213 
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RESULTS AND DISCUSSION 
 
1. BRCA1 AND BRCA2 MUTATIONS ARE FOUND AT A LOW FREQUENCY (I-II)  
 
In the BRCA1 gene, 10 different cancer-predisposing mutations were found, one in each family (Table 7 
and Figure 4). The mutations were unevenly distributed over the BRCA1 gene, with five mutations 
found in exon 11 and five mutations in exons 12-20. Nine of these mutations are truncating mutations. 
The splice site mutation 4216(-2)A>G destroys the invariant AG at the splicing acceptor site 215. This 
splice substitution was not seen in 186 normal control chromosomes. The mutations 1924delA, 
3904C>A, 3744delT, 4216(-2)A>G and 5145-5155del are so far unique to Finland. Of these five 
Finnish mutations, the 3744delT and 4216(-2)A>G have subsequently been found in Finland by another 
research group as well 216. The 2803delAA mutation in exon 11 is also found in Holland, where it is 
present as a founder mutation. The 3604delA is present in Belgium and Holland 217. The 4446C>T has 
been reported several times, in both Europe and Northern America and haplotype studies suggest 
multiple origins for this mutation 82. The 5370C>T mutation is also found also in Austria 218. The 
frameshift mutation 5382insC is found recurrently in Europe and is a Jewish founder mutation 219, 220. 
The cancers occurring in the families carrying mutations in the BRCA1 gene are summarized in Table 
8. 
 
 
Table 7 BRCA1 mutations 
 
Exon Mutation Type Found in  
11 1924delA frameshift Finland 
11 2803delAA frameshift Europe 
11 3604delA frameshift Europe 
11 3744delT frameshift Finland 
11 3904C>A nonsense Finland 
11* 4216(-2)A>G splice site Finland 
13 4446C>T nonsense Europe, North America 
17 5145-5155del frameshift Finland 
20 5370C>T nonsense Europe 
20 5382insC frameshift Europe 
* Intron 10 
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Figure 3 Schematic representation of the distribution of the BRCA1 mutations detected in the mutation 
screening.  
 
 
Seven of the 10 BRCA1 families included ovarian cancer, and three of these families had multiple 
cases. The median age of ovarian cancer onset was 49 years. A statistically significant association (P 
<0.005, Fisher's exact test) between the location of the mutation and prevalence of breast or ovarian 
cancer in the BRCA1 families was discovered. In the five families with exon 11 mutations, a total of 9 
breast cancers and 10 ovarian cancers were seen. On the contrary, in families with mutations 3' of the 
exon 11, a total of 19 breast cancers but only two ovarian cancers were seen. The proposed variation in 
breast and ovarian cancer risk of mutations in different halves of the gene 81 is supported by these data. 
Mutations in the BRCA1 gene also predisposes carriers to prostate and colon cancer 84, however no 
such cases were observed in this set of mutation-positive families. 
 
 
Table 8 Cancer cases in the families with BRCA1 mutations 
 
BRCA1 
mutation 
 
No. of 
BC 
cases 
No. of 
OC  
cases 
Other cancers in family 
1924delA 2 1 skin 
2803delAA 2 2 unknown 
3604delA 1 3 lung 
3744delT 21 1 stomach, skin 
3904C>A 3 3 skin, corpus, pancreas, lung, salivary gland,  peritoneal metastasis2 
4216(-2)A>G 41 0 - 
4446C>T 9 0 lung 
5145-5155del 3 0 gall bladder,  peritoneal metastasis2 
5370C>T 3 1 peritoneal metastasis2  
5382insC 1 1 skin, lymphoma, multiple myeloma 
BC Breast cancer  OC Ovarian cancer 
1 bilateral cases are summarized as two separate cases 
2 primary unknown 
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In the BRCA2 gene, six different mutations were discovered (Table 9 and Figure 5). Four of these are 
recurrent found in more than one family. Four of the mutations lead to premature termination of 
translation. One of these truncating mutations is a combination of a substitution and a deletion in 
positions 6495 and 6496, respectively. Both nucleotide changes reside on the same chromosome, which 
was determined using ASO hybridization with four different oligos detecting different allelic 
combinations. The 9346-2A>G is predicted to destroy the invariant splice acceptor site sequence AG. 
The 9730-12T>G variant is positioned at the conserved run of pyrimidines 215. Neither of these splice-
site substitutions were seen in 186 normal chromosomes and both segregated with the disease in 
families.  
 
 
Table 9 BRCA2 mutations 
 
Exon Mutation Type Found in 
9 999delTCAAA frameshift IcelandR 
11 6495 G>C 
6496delCA 
frameshift Finland 
15 7708 C>T* nonsense FinlandR 
18 8555 T>G nonsense FinlandR 
23** 9346(-2)A>G splice site FinlandR 
25** 9730(-12)T>G splice site Finland 
*    Detected by sequencing 
**  Intron 
R   Recurrent 
 
Five of these BRCA2 mutations are novel Finnish mutations. Two of these five novel mutations 
(999delTCAAA and 9346(-2)A>G) have subsequently been found in other Finnish breast cancer 
families as well 216. The 999delTCAAA has been reported previously as a strong founder mutation in  
Iceland 221. It has not been observed in other Scandinavian countries 222-224. There are two other 
mutations reported in this region, the 1000delAA (reported as 258delAA) and the 995delCAAAT, 
suggesting that this area is a hotspot for mutations 225, 226. Mavraki and coworkers proposed that this 
codon could be associated with increased susceptibility to male breast cancer 225. The absence of male 
breast cancer patients among these Finnish gene carriers does not support this hypothesis. However, it 
should be noted that the number of families is very small. It has been noted that BRCA2 carriers are at 
an increased risk of prostate cancer, and indeed, four cases were observed in these ten families 221. Four 
of these BRCA2 mutations described here were found recurrently. More than one frequent mutation 
may be explained by multiple founder effect with genetic drift in smaller communities, which is 
thereafter mixed to form the larger population 227. In fact, it has been recently shown that carriers of 
these recurrent Finnish BRCA1 and BRCA2 mutations have common ancestors. The variation in the 
length of the shared haplotype indicates that distinct mutations have started to spread at different times 
228. 
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Figure 5 Schematic representation of the distribution of the BRCA2 mutations detected in the mutation 
screening.  
 
 
Table 10 shows the cancer cases occurring in the families carrying BRCA2 mutations. A total of 46 
breast cancer cases were found in the families. Ovarian cancers were detected in seven of these 
families. In addition, other types of malignancies were present in all families.  
 
 
Table 10 Cancer cases in the families with BRCA2 mutations 
 
Mutation No. of   
BC  
cases 
No. of  
OC 
cases 
Other cancers in family 
999delTCAAA 5 0 melanoma, skin1 
999delTCAAA 6* 0 rectum, lung, cervix, corpus uteri, liver, tonsil, prostate 
6496delCA 3 0 stomach, lung, skin1 
7708C>T 6* 1 - 
7708C>T 6 1 prostate, cervix, bladder 
7708C>T 3 1 - 
8555T>G 3* 1 tongue 
8555T>G 5 0 prostate 
9346(-2)A>G 3 1 liver 
9346(-2)A>G 5 2 melanoma, prostate, pancreas 
9730(-12)T>G 1 1 skin1 , lymphoma, multiple myeloma 
BC Breast cancer  OC Ovarian cancer 
* Bilateral cases are summarized as two separate cases 
1 unclassified 
 
Altogether, sixteen different mutations were found in this set of 100 high-risk families. BRCA1 
mutations account for 10% (95% CI = 5-18) of these 100 families and BRCA2 mutations for an 
additional 11% (95% CI = 6-19). The BRCA1 mutations were found more frequently in families with 
both breast and ovarian cancer than in families with breast cancer only. BRCA2 mutations were most 
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common in the largest families with four or more cases of breast cancer or both breast and ovarian 
cancer. Together, mutations in the two genes were found in 12/27 (44%; 95% CI = 25-65) of the breast-
ovarian cancer families and in 4/23 (17%; 95% CI = 5-39) of site specific breast cancer families with 
four or more cases of breast cancer. Only 4/50 (8%, 95% CI = 2-19) of breast cancer families with three 
affected members were mutation-positive. The mutation spectrum is wide in these Finnish families, 
which is consistent with mutation studies in other populations. In summary, a total of 21% (95% CI = 
13-30) of the large breast cancer pedigrees carry mutation in either gene. The proportion of the high-
risk breast cancer families attributable to BRCA1 and BRCA2 has been shown to vary considerably 
between countries. The observed 21 % frequency is lower than in any other country surveyed so far 229. 
 
An early age of breast cancer onset is a clear indicator of BRCA1 as well as BRCA2 mutation carrier 
status in these Finnish breast cancer families. The age of onset in the BRCA1 (median 43.9 years) (P 
<0.0001, unpaired t-test) and in the BRCA2 families (median 49.2 years) (P = 0.0001) was significantly 
lower than in the mutation negative families (median 57.4 years). An older age of onset in the BRCA2 
families compared with BRCA1 families has also been found in other studies 226 and is reflected as a 
smaller contribution of BRCA2 to early onset breast cancer 135. 
 
It is possible that a few mutations have been missed due to limitations of the screening methods used. 
The 7708 C>T mutation in BRCA2 was detected by sequencing previously missed by the 
HA/SSCPmethod. Although the combined use of SSCP with HA offers higher sensitivity, clearly some 
mutations will be missed 188. The methods used in this study lack the capacity to detect gross genomic 
rearrangements comprising several exons. In addition, small in-frame deletions that result in the loss of 
a few residues in the resulting protein would not be detected by the PTT approach 197. This is due to the 
resolution of  the SDS-PAGE method used for separating the produced protein fragments.  A recent 
study revealed that 12% of the mutation-negative families had actually large deletions in the BRCA1 
gene 230. In order to obtain a more accurate frequency of the BRCA1 and BRCA2 mutations in this 
cohort, screening for such deletions is necessary. Mutations involving the promoter region of the 
BRCA1 gene have been reported twice 71, 231, while none have been reported for BRCA2. The 
possibility that promoter-involving mutations are present in the study sample can not be excluded, and 
additional mutation screening is needed to clarify the issue.  
 
In addition, a few families may be explained by the presence of mutations in the TP53 gene, which has 
been shown to account for a small fraction of the high-risk families in Finland. These BRCA1 and 
BRCA2 mutation-negative families fulfilled the criteria of either the Li-Fraumeni syndrome or the Li-
Fraumeni-like syndrome 232. Despite the involvement of other known genes, the results shown here 
strongly suggest that additional yet unidentified breast cancer predisposition genes are likely to be 
important in Finland. 
 
2. BASED ON THE HAPLOTYPE ANALYSIS THERE ARE SEVERAL FAMILIES NOT LINKED 
TO THE BRCA1 OR BRCA2 GENES (II)  
 
In order to confirm the low involvement of these two genes, we also performed haplotype analysis in 
the BRCA1 and BRCA2 regions of chromosome 17q21 and 13q12 in 12 of the larger families where 
mutations had not been found. Not enough samples were available for formal linkage analysis in the 
families, thus, affected family members were studied for sharing alleles, or haplotypes where possible, 
of three microsatellite markers on each chromosome. In seven of these families, linkage to both 
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chromosome 17q21 (BRCA1) and 13q12 (BRCA2) was definitely excluded. Analysis of one breast-
ovarian cancer family suggested linkage to BRCA2. Subsequently the 7708C>T nonsense mutation was 
found in this family by direct sequencing. In four families, analysis was not informative for either the 
BRCA1 or BRCA2 gene. However, no mutations were found by direct sequencing or by PTT and 
HA/SSCP analysis. There was no evidence of a common haplotype between families for which 
exclusion was not obtained. Mutation analysis combined with haplotype analysis suggests that 
additional susceptibility genes may account for a large proportion of breast and breast-ovarian cancer 
families in Finland.  
 
 
3. THE 999delTCAAA MUTATION IN THE BRCA2 GENE IS FOUND IN TWO DIFFERENT 
HAPLOTYPE BACKGROUNDS (IV, UNPUBLISHED)  
 
Haplotype analysis with 24 markers (29 cM) revealed two distinct haplotypes that are associated with 
this mutation in Finland (Table 11, Figure 6). The more common haplotype (denoted as haplotype A) 
was present in 7 families and the rarer haplotype (denoted as haplotype B) in 3 families. The families 
carrying haplotype A all share a common region of approximately 6 cM. The families segregating 
haplotype A originate from two geographical regions: in the old agricultural area Pirkanmaa, and in the 
new settlement region, in the most Eastern part of the country. In haplotype B the core haplotype 
D13S260 to D13S267 (3 cM) is present in all three families with the exception that family 158 carries 
allele 1 (instead of the allele 2) at marker D13S1698. This could be due to mutation 233 or a null allele 
234. All families with haplotype B are located in Pirkanmaa only (Figure 6). The families carrying 
haplotype B have their origins in Pirkanmaa, in the very same small region as the families segregating 
haplotype A. 
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Table 11 The haplotypes in the 999delTCAAA families. The boundaries of the shared region in 
haplotypes between families is indicated by the arrows.  
 
 
 
The presence of two distinct haplotypes supports the hypothesis that this region is in fact is a hotspot. In 
eukaryotic genomes, short tandem repeats are often hotspots for deletions and insertions 235. It has been 
proposed that short symmetric elements predispose DNA sequences to meiotic microdeletion 236and 
indeed, the 999delTCAAA-mutation region is both preceded and followed by such symmetric elements 
(Figure 7). Recurrent mutations with distinct origins have been reported in the BRCA1 gene 237 and a 
similar scenario may be true in the BRCA2 gene.  
 
 
Family
Haplotype A Haplotype B
130
2
2
5
6
4
3
1
2
1
2
2
2
5
1
2
2
2
1
2
6
1
8
1
5
397
7
3
3
6
4
3
1
2
1
2
2
2
5
1
2
2
2
1
2
6
5
5
1
6
D13S283
D13S1294
D13S217
D13S1246
D13S260
SLS312
D13S1699
D13S1698
SLS163
D13S1697
SLS329
7069(+78)del4
D13S1701
SLS321
D13S171
SLS886
D13S1695
D13S1694
D13S1696
D13S267
D13S263
D13S1227
D13S1272
D13S153
2
3
3
6
4
3
1
2
1
2
2
2
5
1
2
2
2
1
2
6
1
5
3
2
63
5
6
3
6
4
3
1
2
1
2
2
2
5
1
2
2
2
1
2
1
7
7
1
3
11
1
6
3
6
4
3
1
2
1
2
2
2
5
1
2
2
2
1
2
6
1
7
1
8
113
2
2
3
6
4
3
1
2
1
2
2
2
5
1
2
2
2
1
2
6
1
5
1
4
97
2
2
3
6
4
3
1
2
1
2
2
2
5
1
2
2
2
1
2
6
1
5
1
4
42
7
2
2
3
7
1
2
2
1
1
1
2
2
1
2
1
3
1
2
4
4
2
2
1
102
1
2
5
5
7
1
2
2
1
1
1
2
2
1
2
1
3
1
2
4
8
6
4
4
4
2
2
1
6
7
1
2
1
1
1
1
2
2
1
2
1
3
1
2
4
8
6
4
4
158Marker
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Figure 6 Map of Finland showing the ancestries of the 999delTCAAA families. The circles indicate 
origins of the families carrying the haplotype A. The triangles indicate origins of the families carrying 
haplotype B. 
 
 
 
 
Figure 7 Sequence of the region encompassing the 999delTCAAA mutation. The deleted 5-bp sequence 
is shown in bold. Symmetric elements on either side of the deleted region are underlined. 
 
 
However, an alternative explanation for two haplotypes in Finland is the occurrence of gene 
conversion. Both haplotypes A and B are present in a very restricted geographical region, in adjacent 
communities in the old agricultural region. Gene conversion becomes possible when a certain allele 
reaches a high frequency in a population and is subsequently mixed with the surrounding one with a 
different haplotype composition. Haplotype B was possibly originally present in a small, geographically 
restricted area that may well have been an isolated sub-population. The gene conversion may have 
occurred when the gene pool of this local isolate was mixed with a larger one due to population growth 
following migration. A situation very similar to the 999delTCAAA has previously been reported in 
Finland in the transglutaminase gene. One mutation was observed in two distinct haplotype 
backgrounds. Both observed haplotypes were present in a restricted geographical region and also 
distinct mutations involving the same genomic region had been described in other populations 238.  
AGTGAAAACACAAATCAAAGAGAAGCTGCAAGTCATG
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4. THE NOVEL BREAST CANCER-PREDISPOSING GENE, BRCA4*, IS LOCATED AT 13q22 (III) 
  
 
Losses in BRCAX* tumors were most often seen at 13q and gains at 1q (Figure 8). The method of 
Brodeur et al. 207. selected the following events as nonrandom in BRCAX cases: +1q, +8q, +16p, +17q, 
+19p, +19q, +20q, -6q, -8p, -9p, -11q, and -13q. The loss of 13q was selected as being an early event in 
the progression of BRCAX tumors with both branching and phylogenetic (distance matrix) trees. In 
contrast, 6q loss was located far from the root of both tree types, suggesting that it may not be an early 
event in the progression of these tumors. 
 
 
 
Figure 8 Gains and losses in the BRCAX tumors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_______________ 
* The novel, yet unidentified, gene was named BRCAX by the authors at the time these analyses were performed. Presently, 
the putative gene is listed in OMIM (2) as BRCA4 (BREAST CANCER, TYPE 4). The designation BRCAX is used instead 
of BRCA4 throughout the text. 
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Compelling evidence implicating 13q loss as an early event in the BRCAX tumors came from one large 
family (L5), where all five samples analyzed from different patients showed a deletion at 13q, with the 
consensus region of deletion at 13q21-q22. Loss of 13q was the only genetic alteration common to all 
five tumors from this family. Several other families showed individual tumors with the same narrow 
region of loss. Loss at 13q was common in samples from each country (Finland 13/24, Sweden 13/23, 
and Iceland 8/14). To test whether losses of the 13q21-q22 region were selected for, because this region 
harbors a germline alteration predisposing to breast cancer, we genotyped genetic markers along the 13q 
region in the germline DNA of the L5 family members. A 7.3 cM haplotype was shared between all five 
affected cases in this family with markers along 13q. The region of sharing was apparent between 
markers D13S1317 and D13S166. Markers at the BRCA2 region were not shared. A metaphase 
fluorescence in situ hybridization experiment localized a yeast artificial chromosome probe for a shared 
genetic marker (D13S1257) to 13q22. This haplotype-sharing region was therefore identical to the 
region of loss in the tumors.  
 
In the targeted linkage analysis 3 markers (D13S1308, D13S1257 and D13S791) had two-point LOD 
scores > 1 in the Finnish population. The peak two-point LOD score (2.89) was observed at D13S1308 
with θ = 0.04. After combination with the Swedish and the Icelandic data, six markers within a 10 cM 
region (D13S1313 to D13S162) had two-point LOD scores greater than 1 (Table 12). The peak LOD 
score was 2.76, θ = 0.10 with marker D13S1308. There was no evidence for sex dependence of the 
recombination fraction. 
 
HOMOG3R analyses showed no evidence of heterogeneity, indicating a low fraction of BRCA1-linked 
families in this data set. The HOMOG2 analyses did not result in significant evidence of heterogeneity 
(p>0.3). This suggests that while there may be a few BRCA2-linked families that were not discovered in 
the extensive mutation detection, the proportion of such families is likely to be small. 
 
Multipoint LOD scores were positive (2.60) between markers D13S1296 and D13S1308. The highest 
HLOD score was 3.46 with the estimated proportion of linked families (α) of 0.65 in the region 
between D13S1296 and D13S1308. The HLODs were positive from D13S1262 to D13S160. 
 
Nonparametric affected sib-pair analysis also supported evidence of linkage at 13q21-q22. The number 
of informative affected sib-pairs ranged from 33 to 65 in the Finnish (mean 50), from two to 12 in the 
Icelandic (mean 7) and from 10 to 23 in the Swedish (mean 20) families. The most significant results 
were obtained in the Finnish families at marker D13S1257 (p=0.003) with D13S1308 showing 
borderline significance (p=0.05). In all 77 families, three markers were slightly positive: D13S1257 
(p=0.015), D13S791 (p=0.05) and D13S269 (p=0.04).  
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Table 12 Combined LOD scores from the 77 families for markers on 13q.  
LOD scores greater than 1.0 are shown in bold. 
 
 LOD score at θ 
Marker 
 
Genetic 
Distance 
cM 
0.00 0.05 0.10 0.20 0.30 0.40 
D13S260*  -8.24 -4.81 -2.92        -1.01        -0.27          -0.04 
D13S1701* 1.6 -4.36 -2.48 -1.43 -0.39 -0.05 0.03 
D13S267* 0 -2.35 -1.16 -0.56 -0.04 0.08 0.06 
D13S1301 20.3 -1.75 -0.69 -0.16 0.23 0.21 0.08 
D13S1313 0.8 0.94 1.13 1.18 0.98 0.56 0.17 
D13S1317 1.9 -1.87 -0.18 0.58 0.96 0.67 0.26 
D13S1262 0 -4.01 -2.03 -1.09 -0.21 0.06 0.07 
D13S275 0.8 -0.24 0.7 0.98 0.87 0.48 0.11 
D13S1296 0.8 -0.27 0.79 1.13 1.05 0.59 0.15 
D13S1308 0 1.61 2.56 2.76 2.19 1.24 0.4 
D13S1291 0.5 -2.64 -0.85 -0.03 0.52 0.41 0.13 
D13S152 2.6 -5.58 -2.12 -0.67 0.41 0.44 0.15 
D13S1257 0 -0.4 0.64 1.14 1.26 0.84 0.3 
D13S745 0 0.63 0.86 0.89 0.68 0.39 0.11 
D13S791 0 -1.55 0.36 0.99 1.09 0.65 0.18 
D13S1326 0 -3.34 -1.2 -0.28 0.32 0.27 0.07 
D13S1249 0.7 -0.45 0.16 0.47 0.59 0.39 0.13 
D13S166 0 -4.93 -2.03 -0.7 0.39 0.45 0.19 
D13S269 1.0 -1.66 -0.2 0.5 0.85 0.56 0.16 
D13S162 1.4 -1.13 0.68 1.39 1.55 0.98 0.33 
D13S1306 1.2 -3.01 -0.98 -0.07 0.51 0.41 0.15 
D13S160 1.8 -2.26 -0.5 0.18 0.47 0.27 0.04 
D13S1255 1.6 -2.87 -1.08 -0.16 0.48 0.4 0.12 
*BRCA2 region 
 
 
Tumor tissue for loss of heterozygosity analysis was available from 16 individuals from six families 
with evidence of linkage to 13q22. Allelic imbalance with multiple markers at 13q22 was observed in 
11/16 cases (69%), whereas the frequency observed in sporadic tumors in this region is 25% 239. In 
eight of the 11 cases, the putative wildtype allele demonstrated loss. LOH provides molecular evidence 
supporting the hypothesis that the gene in this region functions as a tumor suppressor-gene. LOH is 
frequent in both BRCA1 96, 240 and BRCA2 241 with demonstrated loss of the wildtype. It is most 
tempting to speculate that the observed somatic loss of the wildtype allele in these BRCAX tumors 
implies that the new locus at 13q is a classical tumor suppressor gene. 
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A simulation experiment was carried out to validate the significance of the two point linkage score 
empirically. The simulation also addressed the concern that undetected BRCA2 mutation positive 
families had influenced the observed LOD scores at 13q21-q22. We conservatively estimated that the 
upper limit of BRCA2-linked families would be 17/57 Finnish families, 1/12 Icelandic families, and 1/8 
Swedish families. In all possible configurations allowing this number of families to have undetected 
BRCA2 mutations, the simulated LOD score at D13S1308 exceeded the threshold of 2.76 
(corresponding to the peak true LOD score) in at most one of the 3000 replicates. This corresponds to 
significance level of p<0.0017. For a linkage analysis that targets a chromosome no larger than X due to 
substantial prior evidence for linkage, p<0.01 is considered sufficient evidence for linkage 208. 
 
In the 77 families, a maximum two-point LOD score of 2.76 and a peak multipoint HLOD of 3.46 
(alpha = 0.65) were observed. These LOD scores were obtained from a linkage analysis targeting a 
single candidate site in the genome, based on prior suggestions from CGH. This situation is in sharp 
contrast to genome-wide linkage scans where hundreds of comparisons are performed. Therefore, much 
more stringent thresholds for statistical significance need to be applied in genome-wide approaches. 
The two-point linkage result was further evaluated by means of a simulation analysis. Based on 
haplotype sharing at the BRCA2 locus, we modeled that up to 17 Finnish families, one Icelandic family, 
and one Swedish family to be putative BRCA2 families, in which BRCA2 mutations may have been 
missed. This was done to evaluate the influence of putative "contaminating" BRCA2 families on the 
LOD scores observed in the 13q21-q22 region. The simulation results suggested that the observed 
linkage to D13S1308 was significant at a level of P < 0.0017.  
 
In our analyses of BRCA1 and BRCA2 mutation-negative breast cancer families, four intersecting lines 
of evidence suggest that the 13q losses observed in these tumors might represent early, initiating 
genetic alterations. First, the overall frequency of 13q loss was about two times higher in BRCAX 
tumors than in control breast cancers. Second, exploring the CGH data with two different tree models 
placed the loss of 13q at or near the root of the hypothetical breast cancer progression pathways. Third, 
tumor tissues from patients belonging to the same cancer family showed the same specific deletion at 
13q21-q22 and shared a germline haplotype at this locus. Finally, and most importantly, unselected 
BRCAX breast cancer families showed significant evidence of linkage to the 13q21-q22 region. It will 
be critically important to independently validate this genetic locus on larger set of families, especially in 
populations outside of the Nordic countries. Further studies will allow assessment of allelic 
heterogeneity and penetrance estimates. To determine whether any other cancers besides breast cancer 
are present at an elevated level, further study based on this same set of families is necessary. 
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SUMMARY  
 
Identification of individuals at a high-risk of developing breast cancer is a major task. Hereditary breast 
cancer already occurs at a young age and mutation carriers are not detected through general screening 
programs. Determining the incidence of cancer predisposing mutations facilitates further analyses of 
cancer risks and phenotypes associated with specific mutations. These are important parameters when 
establishing genetic testing and counseling. High-risk families also serve as models for understanding 
breast cancer in general, the full extent of associated heterogeneity, and hopefully also interactions of 
environmental and cultural risks. Hereditary breast cancer susceptibility is a complex phenomenon, in 
which multiple genes may play a role. The genes known to be important to the development of cancer 
regulate diverse cellular pathways. The two known breast cancer predisposing genes, BRCA1 and 
BRCA2, are tumor suppressor genes with high penetrance. Both have a function in DNA repair. 
 
The proportion of families in which breast cancer is due to germline BRCA1 and BRCA2 mutations has 
been studied in a cohort of 100 Finnish families with 3 or more affected individuals. In this set of high-
risk breast cancer families a total of 16 different mutations in the BRCA1 and BRCA2 genes were found 
and accounted for 21% of the families analyzed. In the BRCA1 gene, 10 different cancer predisposing 
mutations were identified each in one family. In the BRCA2 gene, six different mutations were 
identified in 11 families, with four recurrent mutations found each in more than one family. The most 
common BRCA2 mutation in Finland, 999delTCAAA, is present in two different haplotype 
backgrounds. Either a hotspot or a gene conversion may explain this finding. The two major breast 
cancer predisposing genes, BRCA1 and BRCA2 are involved in hereditary breast cancer families in 
Finland. Despite the fact that some mutations may have been missed due to the limitations of the 
screening methods used, the majority of the high-risk families are not explained by mutations in these 
two genes. Therefore, the presence of an additional, yet unidentified gene was studied. 
 
The identification of a candidate susceptibility locus at 13q21 was based on a novel strategy, which 
assumed that somatic genetic changes in cancer tissues might give insights into the nature of the 
germline predisposing loci. Detection of somatic deletions in the wildtype gene by comparative 
genomic hybridization in 61 tumors was followed by targeted linkage analysis out in a set of 77 
Finnish, Icelandic, and Swedish breast cancer families. Distinction of early genetic events was 
facilitated by the application of 2 complementary mathematical tree models for analysis of the CGH 
data. The studies predicted that the loss of 13q was one of the earliest genetic events in hereditary 
cancer. In a family with 5 breast cancer cases, all analyzed tumors showed distinct 13q deletions, with 
the minimal region of loss at 13q21-q22. Genotyping revealed segregation of a shared 13q21 germline 
haplotype in the family. In the targeted linkage analysis, a maximum parametric 2-point LOD score of 
2.76 was obtained for a marker at 13q21 (D13S1308, theta = 0.10). The multipoint LOD score under 
heterogeneity was 3.46. The findings provide preliminary evidence for the location of a novel 
predisposition locus for breast cancer at 13q21-q22. 
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